paywalled: How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees (patient safety)

How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees

Purpose

To analyze error disclosure attitudes of radiation oncologists and to correlate error disclosure beliefs with survey-assessed disclosure behavior.

Incidentalome: Accidental Gene Findings You May Not Want To Know | CommonHealth

Incidentalome: Accidental Gene Findings You May Not Want To Know | CommonHealth

What’s All the Fuss about Conflict of Interest in Medical Care? Conflicts of Interest in Medical Care | The Medical Professionalism Blog (re: NY Times article "I Disclose....Nothing"

What’s All the Fuss about Conflict of Interest in Medical Care?

Written by Daniel Wolfson on February 10, 2012
 

"A couple of weeks ago, the New York Times published a story entitled I Disclose…Nothing by Elisabeth Rosenthal. The premise of the article dealt with conflicts of interests in several professions, including those in medicine. It got me thinking about whether or not the concept of disclosure can successfully manage conflicts of interest in medicine as much as people expect it to.
The conclusion I came up with, in short, was no....."

New York Times - News Analysis - "I Disclose ... Nothing" (patient safety communities ??)

"........One fundamental problem is that disclosure requirements merely get information onto the table, but themselves demand no further action. According to political theory, disclosure is both a citizen’s right and a tool to ensure good government and consumer protection, because it provides information that leads to informed decisions. Instead, disclosure has often become an endpoint in the chain of responsibility, an act of compliance with the letter of the law rather than the spirit of transparency....."

"“In the beginning, disclosure was a means to an end, and now it’s often an end in itself,” said Kevin P. Weinfurt, professor of psychiatry and behavioral science at Duke University. “People think, ‘If we’ve disclosed we’ve fulfilled our responsibilities.’ ”

Comment on "Training Surgeons and the Informed Consent Process: Routine Disclosure of Trainee Participation and Its Effect on Patient Willingness and Consent Rates"

Medscape: Most Parents Disclose Cancer Gene Results to Children

1) Medscape link

 January 10, 2012 — The majority of parents who are tested for BRCA1 and BRCA2 genes share those results with their children. In fact, a number of parents even discuss the results with very young children, according to a study published online January 9 in Cancer....

2) Cancer Journal

link to abstract:  When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response

full free access: PLoS ONE: Antidepressants and Breast and Ovarian Cancer Risk: A Review of the Literature and Researchers' Financial Associations with Industry

Background

Antidepressant (AD) use has been purported to increase the risk of breast and ovarian cancer, although both epidemiological and pre-clinical studies have reported mixed results [1]–[6]. Previous studies in a variety of biomedical fields have found that financial ties to drug companies are associated with favorable study conclusions [7].......

It is recommended that future research examine this body of literature and investigate the association between industry funding and qualitative conclusions regarding cancer risk.

Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices -- American Journal of Public Health selected articles

Note: this journal is by subscription ($$$)

AJPH First Look, published online ahead of print Jan 13, 2011

April 2011, Vol 101, No. 4 | American Journal of Public Health 602-609
© 2011 American Public Health Association
DOI: 10.2105/AJPH.2010.300027

GOVERNMENT, POLITICS, AND LAW

Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices
Sheila M. Rothman, PhD, Victoria H. Raveis, PhD, Anne Friedman, BA and David J. Rothman, PhD
Sheila M. Rothman is with the Division of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, and the Center for the Study of Society and Medicine,

College of Physicians and Surgeons, Columbia University. Victoria H. Raveis is with the Psychosocial Unit on Health, Ageing, and Community, New York University College of Dentistry, New

York. At the time of the study Anne Friedman was with the Center on Medicine as a Profession, College of Physicians and Surgeons, Columbia University. David J. Rothman is with the College
of Physicians and Surgeons, Columbia University.
Correspondence: Correspondence should be sent to Sheila M. Rothman, Center for the Study of Society and Medicine, College of Physicians and Surgeons, Columbia University,

630 West 168th St, PH 15-25, New York, NY 10032 (e-mail: smr4@columbia.edu). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" button.
Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's
marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed.
We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns.

Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor.

No HAO disclosed the exact amount of a Lilly grant.
As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators,

and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.




This article has been cited by other articles:

				M. Weinberg Patient Advocacy Organizations and Corporate Relationships Am J Public Health, April 1, 2011; 101(4): 582 - 583. [Full Text] [PDF]

eLetters:

Read all eLetters

Health Advocacy Organizations: Transparency is important and so is evidence

Frances M Visco

AJPH Online, 17 Jan 2011 [Full text]

Patient Advocacy Organizations are Committed to Transparency

Myrl Weinberg

AJPH Online, 20 Jan 2011 [Full text]

Re: Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis

Jack Harris, et al.

AJPH Online, 24 Jan 2011 [Full text]

Patient groups must reveal corporate sponsorship, urges campaign group - BMJ

Clinical Trial Participants Are There Willingly - in Public Health & Policy, Clinical Trials

JAMA -- Incomplete Financial Disclosure in: A 70-Year-Old Woman With Shingles: Review of Herpes Zoster, January 26, 2010, 0 (2010): 2010.110